BR112014010139A2 - formulação farmacêutica, método de redução do nível de açúcar no sangue de um paciente e polipeptídeo - Google Patents

formulação farmacêutica, método de redução do nível de açúcar no sangue de um paciente e polipeptídeo

Info

Publication number
BR112014010139A2
BR112014010139A2 BR112014010139A BR112014010139A BR112014010139A2 BR 112014010139 A2 BR112014010139 A2 BR 112014010139A2 BR 112014010139 A BR112014010139 A BR 112014010139A BR 112014010139 A BR112014010139 A BR 112014010139A BR 112014010139 A2 BR112014010139 A2 BR 112014010139A2
Authority
BR
Brazil
Prior art keywords
polypeptide
patient
reducing
pharmaceutical formulation
blood sugar
Prior art date
Application number
BR112014010139A
Other languages
English (en)
Portuguese (pt)
Inventor
Weiss Michael
Original Assignee
Univ Case Western Reserve
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Case Western Reserve filed Critical Univ Case Western Reserve
Publication of BR112014010139A2 publication Critical patent/BR112014010139A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Microbiology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
BR112014010139A 2011-10-27 2012-10-29 formulação farmacêutica, método de redução do nível de açúcar no sangue de um paciente e polipeptídeo BR112014010139A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161552246P 2011-10-27 2011-10-27
PCT/US2012/062423 WO2013063572A1 (en) 2011-10-27 2012-10-29 Ultra-concentrated rapid-acting insulin analogue formulations

Publications (1)

Publication Number Publication Date
BR112014010139A2 true BR112014010139A2 (pt) 2017-04-25

Family

ID=48168643

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014010139A BR112014010139A2 (pt) 2011-10-27 2012-10-29 formulação farmacêutica, método de redução do nível de açúcar no sangue de um paciente e polipeptídeo

Country Status (10)

Country Link
US (1) US9908925B2 (enExample)
EP (1) EP2771026A4 (enExample)
JP (1) JP2014533241A (enExample)
KR (1) KR20150021011A (enExample)
CN (1) CN104010652A (enExample)
AU (1) AU2012328407A1 (enExample)
BR (1) BR112014010139A2 (enExample)
IN (1) IN2014CN03888A (enExample)
SG (1) SG11201401835VA (enExample)
WO (1) WO2013063572A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2015005662A (es) * 2012-11-05 2015-08-20 Univ Case Western Reserve Analogos de insulina de una sola cadena de larga accion.
WO2015106269A2 (en) 2014-01-13 2015-07-16 Thermalin Diabetes, Llc Rapid action insulin formulations and pharmaceutical delivery systems
AR099569A1 (es) 2014-02-28 2016-08-03 Novo Nordisk As Derivados de insulina y los usos médicos de estos
CA2964918A1 (en) * 2014-10-20 2016-04-28 Case Western Reserve University Halogenated insulin analogues of enhanced biological potency
SG10201809457YA (en) * 2014-11-21 2018-11-29 Merck Sharp & Dohme Insulin receptor partial agonists
WO2016105545A2 (en) * 2014-12-24 2016-06-30 Case Western Reserve University Insulin analogues with enhanced stabilized and reduced mitogenicity
WO2017032795A1 (en) 2015-08-25 2017-03-02 Novo Nordisk A/S Novel insulin derivatives and the medical uses hereof
CA2996455A1 (en) 2015-08-25 2017-03-02 Novo Nordisk A/S Novel insulin derivatives and the medical uses hereof
EP3341402A1 (en) 2015-08-25 2018-07-04 Novo Nordisk A/S Novel insulin derivatives and the medical uses hereof
WO2017070617A1 (en) * 2015-10-21 2017-04-27 Case Western Reserve University Diol-modified insulin analogues containing a glucose-regulated conformational switch
SG11201803911PA (en) 2015-12-23 2018-07-30 Univ Case Western Reserve Encapsulation of ultra-stable insulin analogues with polymer melts
SG11202106168VA (en) * 2018-12-11 2021-07-29 Sanofi Sa Insulin analogs having reduced insulin receptor binding affinity
FI4073097T3 (fi) 2019-12-11 2024-08-13 Novo Nordisk As Uusia insuliinianalogeja ja niiden käyttötapoja
WO2024194897A1 (en) * 2023-03-22 2024-09-26 Council Of Scientific And Industrial Research An Indian Registered Body Incorporated Under The Regn. Of Soc. Act (Act Xxi Of 1860) A glycation resistant insulin polypeptide and a method of preparing the same thereof

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4992418A (en) * 1987-07-17 1991-02-12 Mount Sinai School Of Medicine Superactive human insulin analogue-[10-Aspartic Acid-B]Human Insulin
ATE93238T1 (de) 1988-07-20 1993-09-15 Novo Nordisk As Menschliche insulinanalage und zubereitungen daraus.
US5474978A (en) 1994-06-16 1995-12-12 Eli Lilly And Company Insulin analog formulations
US20030104981A1 (en) * 1995-11-03 2003-06-05 Jelena Mandic Human insulin analogues
DE10114178A1 (de) 2001-03-23 2002-10-10 Aventis Pharma Gmbh Zinkfreie und zinkarme Insulinzubereitungen mit verbesserter Stabilität
US7317000B2 (en) 2001-12-02 2008-01-08 Novo Nordisk A/S Glucose-dependent insulins
WO2003048195A2 (en) 2001-12-02 2003-06-12 Novo Nordisk A/S Glucose dependant release of insulin from glucose sensing insulin derivatives
RU2005131429A (ru) * 2003-03-11 2006-05-10 Ново Нордиск А/С (DK) Фармацевтические препараты, включающие кислотно-стабилизированный инсулин
SE0401942D0 (sv) 2004-07-28 2004-07-28 Lipopeptide Ab New antimicrobial peptide complexes
US20100298213A1 (en) 2004-08-20 2010-11-25 Novo Nordisk A/S Pharmaceutically Active Insulin Receptor-Modulating Molecules
ES2554773T3 (es) * 2006-10-04 2015-12-23 Case Western Reserve University Insulina y análogos de la insulina resistentes a la fibrilación
US8946148B2 (en) 2007-11-20 2015-02-03 Ambrx, Inc. Modified insulin polypeptides and their uses
KR20110061552A (ko) * 2008-07-31 2011-06-09 케이스 웨스턴 리저브 유니버시티 할로겐 안정화된 인슐린
KR20120129875A (ko) * 2008-07-31 2012-11-28 케이스 웨스턴 리저브 유니버시티 염소화 아미노산을 갖는 인슐린 유사체
WO2010080606A1 (en) * 2008-12-19 2010-07-15 Indiana University Research And Technology Corporation Insulin analogs

Also Published As

Publication number Publication date
EP2771026A4 (en) 2015-08-05
IN2014CN03888A (enExample) 2015-10-16
WO2013063572A1 (en) 2013-05-02
EP2771026A1 (en) 2014-09-03
KR20150021011A (ko) 2015-02-27
US9908925B2 (en) 2018-03-06
NZ624493A (en) 2016-02-26
SG11201401835VA (en) 2014-09-26
AU2012328407A1 (en) 2014-05-22
JP2014533241A (ja) 2014-12-11
US20140323398A1 (en) 2014-10-30
CN104010652A (zh) 2014-08-27

Similar Documents

Publication Publication Date Title
BR112014010139A2 (pt) formulação farmacêutica, método de redução do nível de açúcar no sangue de um paciente e polipeptídeo
HUS2100018I1 (hu) Hatóanyagok légúti beadására alkalmas készítmények és ezekkel kapcsolatos eljárások
IL264649B (en) Raav-guanylate cyclase compositions and methods for treating leber's congenital amaurosis-1 (lca1)
EP2768571A4 (en) MEDICAL ACTIVE COMPOSITION DEVICE
DK2641614T3 (da) Farmaceutisk præparat integreret med mikronåle til hudbehandling
IL260585B (en) Compositions and methods for treating retinal diseases
ZA201400616B (en) Methods and devices for drug delivery to ocular tissue using microneedle
EP2593039A4 (en) MEDICAL ACTIVE COMPOSITION DEVICE
EP3466408C0 (en) LIQUID PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF A DISEASE OF THE POSTERIOR EYE
FI20116115A7 (fi) Menetelmä ja järjestelmä henkilön fysiologisen tilan kartoittamiseksi
BR112014014262A2 (pt) nanopartículas; composição farmacêutica; método de administrar um ou mais agentes terapêuticos, profiláticos, e/ou diagnósticos a um paciente em necessidade dos mesmos e método de preparação das partículas.
EP2411083A4 (en) MEDICAL ACTIVE COMPOSITION DEVICE
BR112012032948A2 (pt) dispositivos injectores e método de suprimento de solução oftálmica à córnea do olho
HUE043540T2 (hu) Szubsztituált dimer kinazolin-származék, elõállítása, valamint alkalmazása 1-es és 2-es típusú cukorbetegség kezelésére szolgáló gyógyászati készítményekben
BR112013015855A2 (pt) composto, uso de um composto, métodos de prevenção, tratamento, melhora ou profilaxia de distúrbios fisiológicos ou doenças, e de tratamento ou melhora de indicações cosméticas, e, composição farmacêutica.
WO2011088120A8 (en) Antibody formulation and therapeutic regimens
EP2670458A4 (en) APPARATUS FOR MEDICAMENT ADMINISTRATION
IL219787B (en) Methods of producing human rpe cells and pharmaceutical preparations of human rpe cells
BR112013015859A2 (pt) composto, uso de um composto, métodos de prevenção, tratamento, melhora ou profilaxia de distúrbios fisiológicos ou doenças, e de tratamento ou melhora de indicações cosméticas, e, composição farmacêutica
PL2464342T3 (pl) Formulacje farmaceutyczne do zapobiegania niewłaściwemu użyciu leków medycznych
BR112012027545A2 (pt) composto de fórmula i, composição farmacêutica, uso da composição farmacêutica, uso de um composto e método de modulação do nível de glicose no sangue em um indivíduo
BR112013009970A2 (pt) método para determinar uma característica do ritmo circadiano de um paciente.
EP2731594A4 (en) CAPSULE FORMULATION WITH MONTELUKAST AND LEVOCETIRIZIN
ZA201505849B (en) Composition of novel carbohydrate drug for treatment of human diseases
IL230957A0 (en) Pharmacy methods and preparations for the treatment of an eye disease in a patient

Legal Events

Date Code Title Description
B08F Application fees: application dismissed [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2435 DE 05-09-2017 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.

B350 Update of information on the portal [chapter 15.35 patent gazette]